Huntington Disease — Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Citation(s)
A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).